| 1 |
34969744 | Correlation Between Clinical Outcomes and Serum CA-125 Levels After Standard Treatment for Epithelial Ovarian Cancer. | 2022 Jan |
2 |
| 2 |
33397458 | Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer. | 2021 Jan 4 |
6 |
| 3 |
33423683 | Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer. | 2021 Jan 11 |
1 |
| 4 |
33919797 | Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma. | 2021 Apr 14 |
1 |
| 5 |
31970128 | Potential predictors for chemotherapeutic response and prognosis in epithelial ovarian, fallopian tube and primary peritoneal cancer patients treated with platinum-based chemotherapy. | 2020 Jan |
1 |
| 6 |
32771026 | Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications. | 2020 Aug 8 |
1 |
| 7 |
32791996 | Nadir CA-125 serum levels during neoadjuvant chemotherapy and no residual tumor at interval debulking surgery predict prognosis in advanced stage ovarian cancer. | 2020 Aug 13 |
1 |
| 8 |
30755819 | Serum CA125 and ascites leptin level ratio predicts baseline clinical resistance to first-line platinum-based treatment and poor prognosis in patients with high grade serous ovarian cancer. | 2019 |
1 |
| 9 |
28842710 | Preoperative prognostic nutritional index is a powerful predictor of prognosis in patients with stage III ovarian cancer. | 2017 Aug 25 |
1 |
| 10 |
27069172 | Dynamic Analysis of CA125 Decline During Neoadjuvant Chemotherapy in Patients with Epithelial Ovarian Cancer as a Predictor for Platinum Sensitivity. | 2016 Apr |
4 |
| 11 |
27172742 | Has serum CA 125 assay at the time of relapse a prognostic relevance for patients with recurrent ovarian carcinoma after primary cytoreduction and platinum- and paclitaxel-based chemotherapy? | 2016 |
1 |
| 12 |
27358387 | Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer? | 2016 Aug |
1 |
| 13 |
27407100 | Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial. | 2016 Aug |
2 |
| 14 |
27677313 | Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer. | 2016 Sep 27 |
2 |
| 15 |
27793850 | Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. | 2016 Nov |
1 |
| 16 |
25667499 | Correlation between CA125 levels after sixth cycle of chemotherapy and clinical outcome in advanced ovarian carcinoma. | 2015 Feb |
1 |
| 17 |
22033034 | CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study. | 2012 Feb |
1 |
| 18 |
20705911 | A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. | 2011 Feb |
1 |
| 19 |
22093929 | [Prediction of chemoresistance in epithelial ovarian cancer by clinical factors]. | 2011 Aug 9 |
1 |
| 20 |
22180399 | Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed. | 2011 Dec |
2 |
| 21 |
19396000 | Clinical utility of CA-125 for maintenance therapy in the treatment of advanced stage ovarian carcinoma. | 2009 Feb |
1 |
| 22 |
19447480 | The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer. | 2009 Aug |
1 |
| 23 |
19548140 | Utility of gene promoter methylation in prediction of response to platinum-based chemotherapy in epithelial ovarian cancer (EOC). | 2009 Oct |
1 |
| 24 |
18329083 | Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study. | 2008 May |
3 |
| 25 |
18768214 | CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy. | 2008 Nov |
1 |
| 26 |
16595148 | Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. | 2006 Oct |
2 |
| 27 |
15047226 | The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. | 2004 Apr |
4 |
| 28 |
14529671 | Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. | 2003 Oct |
1 |
| 29 |
12082455 | A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. | 2002 Jul |
1 |
| 30 |
10080591 | Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. | 1999 Feb |
1 |
| 31 |
3308479 | The clinical value of serum CA125 levels in ovarian cancer patients receiving platinum therapy. | 1987 Jun |
2 |